2006
A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy.
Longo D, Glatstein E, Duffey P, Young R, Fiem S, Jaffe E, Camphausen K, Wilson W, DeVita V. A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy. Blood 2006, 108: 98. DOI: 10.1182/blood.v108.11.98.98.Peer-Reviewed Original ResearchStage IA diseaseDisease-free survivalComplete responseModality therapyHodgkin's diseaseRadiation therapyMOPP chemotherapyFirst remissionIA diseaseOverall survivalSecond cancersSignificant treatment toxicityStage Hodgkin's diseaseCombined modality therapyRadiation-treated patientsIIIA Hodgkin's diseaseAdministration of radiationInitial remissionProspective trialTreatment toxicityCombination chemotherapyIA patientsLate effectsPatientsMOPP
1999
Hodgkin's disease and transplantation: a room with a (nontransplanter's) view.
Marshall N, DeVita V. Hodgkin's disease and transplantation: a room with a (nontransplanter's) view. Seminars In Oncology 1999, 26: 67-73. PMID: 10073563.Peer-Reviewed Original ResearchConceptsHigh-dose chemotherapyPeripheral blood stem-cellHodgkin's diseaseOverall survivalRefractory diseaseDisease-freeBone marrowPeripheral blood stem-cell supportGraft-versus-host disease prophylaxisManagement of refractory diseasePatients potential candidatesImprove disease-freePatients disease-freeFollow-up timeShort follow-up timeResponse to treatmentSalvage chemotherapyApproach to treatmentCombination chemotherapyDose intensityTransplant supportAllograft patientsInitial remissionRelapse rateDisease prophylaxis
1997
Late sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1992
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, DeVita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal Of Clinical Oncology 1992, 10: 210-8. PMID: 1732422, DOI: 10.1200/jco.1992.10.2.210.Peer-Reviewed Original ResearchConceptsComplete response rateInitial remissionComplete remissionCombination chemotherapyHodgkin's diseaseSalvage therapyOverall survivalPeripheral blood stem cell supportResponse rateChemotherapy-induced complete remissionConventional-dose salvage therapyDate of relapseDurable second remissionsRemission 5 yearsSalvage combination chemotherapyShort initial remissionTreatment-related complicationsDisease-free survivalClinical prognostic factorsStem cell supportDuration of responsePrimary treatment regimenRelapse of patientsNational Cancer InstituteB symptoms
1991
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaCo-trimoxazole prophylaxisComplete response rateDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rate
1989
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Longo D, Glatstein E, Duffey P, Ihde D, Hubbard S, Fisher R, Jaffe E, Gilliom M, Young R, DeVita V. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. Journal Of Clinical Oncology 1989, 7: 1295-302. PMID: 2788716, DOI: 10.1200/jco.1989.7.9.1295.Peer-Reviewed Original ResearchConceptsInvolved field radiation therapyRadiation therapyComplete remissionAggressive lymphomaCoronary artery bypass surgeryInvolved-field radiation therapyEarly hematogenous disseminationLocalized aggressive lymphomaTreatment-related deathsClinical stage IHigh-dose methotrexateArtery bypass surgeryCombination chemotherapy programsCycles of treatmentMedian followAggressive histologyBypass surgeryLeucovorin rescueChemotherapy programCombination chemotherapyHospital admissionLocal therapyHematogenous disseminationEffective treatmentLymphoma histology
1988
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone A, Longo D, DeVita V, Ihde D, Duffey P, Jaffe E, Solomon D, Hubbard S, Young R. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal Of Clinical Oncology 1988, 6: 1832-7. PMID: 3199167, DOI: 10.1200/jco.1988.6.12.1832.Peer-Reviewed Original ResearchConceptsResidual abdominal massesClinical complete remissionAbdominal massAggressive lymphomaNational Cancer InstituteStable residual massComplete remissionCombination chemotherapyPathologic evaluationFull-dose combination chemotherapyResidual massSubsequent tumor necrosisViable lymphoma cellsEvidence of diseaseMonths of chemotherapyInitial tumor sizeRestaging laparotomyBulky diseaseNegative laparotomyDisseminated diseaseIntraabdominal diseaseMost patientsSurgical explorationResidual tumorResidual diseaseThe treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Young R, Longo D, Glatstein E, Ihde D, Jaffe E, DeVita V. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars In Hematology 1988, 25: 11-6. PMID: 2456618.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideEvaluation Studies as TopicHumansLeucovorinLeukemiaLeukemia, Radiation-InducedLymph NodesLymphoma, Non-HodgkinMechlorethamineMethotrexateNeoplasms, Multiple PrimaryNeoplasms, Radiation-InducedPalliative CarePrednisoneProcarbazineRandom AllocationVincristineConceptsAdvanced indolent lymphomaLimited radiation therapyTotal nodal irradiationIndolent lymphomaRadiation therapyModality treatmentInitial treatmentAggressive combined modality therapyCombined modality therapyEvaluable patientsInduction therapyInitial therapyNodal irradiationFirst remissionInitial remissionFrequent relapsesMedian durationModality therapySystemic therapyCombination chemotherapyMedian timeHistologic progressionLonger survivalPatient's diseasePatientsThe role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapy
1987
The evolution of chemotherapy of lymphomas of adults.
DeVita V. The evolution of chemotherapy of lymphomas of adults. Leukemia 1987, 1: 467-85. PMID: 3312842.Peer-Reviewed Original Research
1985
Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy.
Geffen D, Fisher R, Longo D, Young R, DeVita V. Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. Journal Of Clinical Oncology 1985, 3: 646-53. PMID: 3998781, DOI: 10.1200/jco.1985.3.5.646.Peer-Reviewed Original ResearchConceptsNormal renal functionSerum creatinine levelsRenal involvementDiffuse aggressive lymphomasRenal functionCombination chemotherapyCreatinine levelsAggressive lymphomaElevated serum creatinine levelInitial local controlRecurrent renal diseaseEvidence of diseaseSite of recurrenceResults of treatmentComplete remissionDisseminated diseaseRenal diseaseSystemic diseaseHodgkin's lymphomaComplete resolutionRadiographic criteriaPatientsLocal controlLymphomaChemotherapyProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher R, Young R, Longo D, DeVita V. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Seminars In Oncology 1985, 12: 29-32. PMID: 2579441.Peer-Reviewed Original ResearchConceptsComplete remissionCombination chemotherapyAdvanced stageComplete response rateLong-term survivalMOPP combination chemotherapyC-MOPPComplete respondersNew regimenHodgkin's lymphomaBurkitt's lymphomaDiffuse lymphomaResponse rateFatal diseaseLymphomaPatientsDeath rateNCI studyHigh gradeRemissionChemotherapyDiseaseLarge cellsMyelosuppressionRegimenTreatment of diffuse large cell non-Hodgkin’s lymphomas
Fisher R, Devita V, Longo D, Ihde D, Young R. Treatment of diffuse large cell non-Hodgkin’s lymphomas. Developments In Oncology 1985, 465-469. DOI: 10.1007/978-1-4613-2607-6_49.Peer-Reviewed Original ResearchLong-term disease-free survivalDisease-free survivalAdvanced stageAdvanced diffuse histiocytic lymphomaDiffuse mixed lymphomaDiffuse histiocytic lymphomaDiffuse large cellDiffuse aggressive lymphomasLarge cell lymphomaComplete remissionComplete respondersCombination chemotherapyMixed lymphomaAggressive lymphomaHodgkin's lymphomaHistiocytic lymphomaTherapeutic resultsCell lymphomaBurkitt's lymphomaLymphomaFatal diseaseTreatment programPatientsSurvivalLarge cells
1983
Advances in cancer therapeutics: chemotherapy.
DeVita V. Advances in cancer therapeutics: chemotherapy. Progress In Clinical And Biological Research 1983, 132A: 47-69. PMID: 6634746.Peer-Reviewed Original ResearchConceptsTumor massEffectiveness of combination chemotherapyResistance to anti-cancer drugsCancer chemotherapyInvariable inverse relationshipPathways of drug resistanceOutcome of cancer chemotherapyOutcome of surgeryResistance to chemotherapyCell numberHistory of cancerNatural history of cancerOrigin of human cancerCombination chemotherapyAnti-cancer drugsLocal treatmentChemotherapyDrug resistanceHuman malignanciesRadiotherapyCancer therapeuticsNatural historyHuman cancersSurgeryCancer
1982
Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute
Anderson T, Devita V, Simon R, Berard C, Canellos G, Garvin A, Young R. Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute. Cancer 1982, 50: 2708-2721. PMID: 7139564, DOI: 10.1002/1097-0142(19821215)50:12<2708::aid-cncr2820501203>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsHistologic typeDiffuse histologic typeComplete responseNational Cancer InstitutePrognostic factorsLymphoma patientsLymphocytic lymphomaCancer InstituteHigh complete response rateDiffuse lymphoma patientsModern radiotherapeutic techniquesNodular lymphocytic lymphomaNodular lymphoma patientsSimilar treatment regimensComplete response rateImportant prognostic factorStage of diseaseCS ICS IIICS IVB symptomsCombination chemotherapyIV patientsHistologic subtypePatient sexHistologic Progression in Non-Hodgkin’s Lymphoma
Hubbard S, Chabner B, DeVita V, Simon R, Berard C, Jones R, Garvin A, Canellos G, Osborne C, Young R. Histologic Progression in Non-Hodgkin’s Lymphoma. Blood 1982, 59: 258-264. DOI: 10.1182/blood.v59.2.258.258.Peer-Reviewed Original ResearchNodular lymphomaHistological progressionLymphoma patientsHistiocytic cell typesProlonged disease-free survivalNon-Hodgkin's lymphoma patientsAssociated with prolonged survivalCell typesIntensive combination chemotherapyNon-Hodgkin's lymphomaDisease-free survivalResponse to chemotherapyNon-HodgkinCombination chemotherapyDiffuse histologyIntensive chemotherapyClinical courseBiopsy specimensProlonged survivalWorsened prognosisLymphomaNodular patternBiopsyClinical trialsDrug treatment
1981
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma
Broder S, Callihan T, Jaffe E, DeVita V, Strober W, Bartter F, Waldmann T. Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. Gastroenterology 1981, 80: 166-168. PMID: 7450403, DOI: 10.1016/0016-5085(81)90208-0.Peer-Reviewed Original ResearchConceptsIntestinal lymphangiectasiaCombination chemotherapyMalignant lymphomaUndifferentiated malignant lymphomaSystemic combination chemotherapyGastrointestinal protein lossProtein lossB-cell originSerum protein concentrationMonoclonal B-cell originGastrointestinal symptomsRecurrent vomitingMassive edemaIntestinal lymphangiectasisIntestinal lymphaticsGastrointestinal tractNeoplastic cellsPatientsLymphomaLymphangiectasiaInitial evaluationYr durationChemotherapyEdemaDisease
1980
The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications.
Garvin A, Simon R, Young R, DeVita V, Berard C. The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications. Seminars In Oncology 1980, 7: 234-43. PMID: 6998002.Peer-Reviewed Original ResearchConceptsLukes-Collins systemNon-Hodgkin's lymphomaLukes-CollinsClassification of non-Hodgkin's lymphomasClinical management of patientsAggressive combination chemotherapyDiffuse histiocytic lymphomaHomogeneous group of patientsManagement of patientsGroup of patientsB symptomsLymphocytic lymphomaCentroblastic-centrocyticCombination chemotherapyDiffuse lymphomaLymphoblastic lymphomaPlasmacytoid differentiationKiel classificationRappaport classificationNodular lymphomaHistiocytic lymphomaRetrospective reviewFollicular patternClinicopathologic entityYounger patientsNodular Histiocytic Lymphoma: An Aggressive Nodular Lymphoma With Potential for Prolonged Disease-Free Survival
Osborne C, Norton L, Young R, Garvin A, Simon R, Berard C, Hubbard S, DeVita V. Nodular Histiocytic Lymphoma: An Aggressive Nodular Lymphoma With Potential for Prolonged Disease-Free Survival. Blood 1980, 56: 98-103. DOI: 10.1182/blood.v56.1.98.98.Peer-Reviewed Original ResearchNodular histiocytic lymphomasDiffuse histiocytic lymphomaHistiocytic lymphomaNodular lymphomaPathological stageProlonged disease-free survivalNatural historyDisease-free survivalLymph node biopsyNon-Hodgkin's lymphomaSubtypes of lymphomaTreated with cyclophosphamideLymph node examinationLymph node histologyGroup of patientsLong-term survivorsNode biopsyCombination chemotherapyNode examinationLiver involvementNode histologyLymphomaTherapeutic strategiesPatientsLymph